Association of Insulin Glargine Treatment with Bone Mineral Density in Patients with Type 2 Diabetes Mellitus

Overview

Journal Diabetes Metab Syndr Obes

Publisher Dove Medical Press

Specialty Endocrinology

Date 2021 May 6

PMID 33953588

Citations 4

Authors

Dan Liu

Jing-Jie Bai

Jun-Jie Yao

Yong-Bo Wang

Tong Chen

Qian Xing

Ran Bai

Affiliations

Soon will be listed here.

Abstract

Purpose: To assess the association of type 2 diabetes mellitus (T2DM) and insulin glargine treatment with bone mineral density (BMD) in Chinese people.

Methods: This retrospective study included 50 subjects with T2DM: 25 received oral glucose-lowering medication (ORL group), and 25 received oral glucose-lowering medication in combination with insulin glargine injection (CGI group). Thirty non-diabetic control subjects were also included. BMD was measured at lumbar vertebrae 1-4 (L1-L4), spine bone mineral density (sBMD) results summary (L2-L4), femoral neck and trochanter by dual-energy x-ray absorptiometry.

Results: Compared with non-diabetic controls, people with T2DM had significantly lower mean BMD at L2 (1.073±0.120 vs 0.984±0.158), L3 (1.094±0.129 vs 0.991±0.163) and L4 (1.089±0.130 vs 0.982±0.165) (all P<0.05), significantly lower levels of serum calcium (2.02±0.22 vs 2.27±0.17 mmol/L, P<0.05), PTH (24.19±9.71 vs 31.52±8.96 pg/mL, P<0.05), and higher serum phosphate levels (1.43±0.37 vs 1.20±0.15 mmol/L, P<0.05). The CGI group had higher L2, L3 and L4 BMD and sBMD (L2-L4) (P<0.05), higher serum calcium levels (2.19±0.11 vs 1.98±0.20 mmol/L, P<0.05) and lower serum phosphate levels (1.28±0.20 vs 1.58±0.43 mmol/L, P<0.05) versus the ORL group. BMD and serum calcium levels were associated with the application of insulin glargine.

Conclusion: These results suggest that insulin glargine may affect bone metabolism in patients diagnosed with T2DM. The study has implications for the selection of hypoglycemic agents for diabetic patients at risk of osteoporosis.

Citing Articles

Effect of Antidiabetic Drugs on Bone Health in Patients with Normal Renal Function and in Chronic Kidney Disease (CKD): Insight into Clinical Challenges in the Treatment of Type 2 Diabetes.

Cipriani C, Lauriero G, Tripepi G, Ferrari S, Bover J, Ravera M J Clin Med. 2023; 12(23).

PMID: 38068310 PMC: 10707671. DOI: 10.3390/jcm12237260.

The effects of exenatide and insulin glargine treatments on bone turnover markers and bone mineral density in postmenopausal patients with type 2 diabetes mellitus.

Akyay O, Canturk Z, Selek A, Cetinarslan B, Tarkun I, Cakmak Y Medicine (Baltimore). 2023; 102(39):e35394.

PMID: 37773814 PMC: 10545322. DOI: 10.1097/MD.0000000000035394.

Comparison of the effect of Dapagliflozin and Pioglitazone on the risk of osteoporosis in postmenopausal women with Type-2 diabetes.

Son O Pak J Med Sci. 2023; 39(5):1238-1242.

PMID: 37680820 PMC: 10480740. DOI: 10.12669/pjms.39.5.7580.

A Review on the Crosstalk between Insulin and Wnt/β-Catenin Signalling for Bone Health.

Wong S, Mohamad N, Jayusman P, Ibrahim N Int J Mol Sci. 2023; 24(15).

PMID: 37569816 PMC: 10419059. DOI: 10.3390/ijms241512441.

References

Xia J, Zhong Y, Huang G, Chen Y, Shi H, Zhang Z . The relationship between insulin resistance and osteoporosis in elderly male type 2 diabetes mellitus and diabetic nephropathy. Ann Endocrinol (Paris). 2012; 73(6):546-51. DOI: 10.1016/j.ando.2012.09.009. View

Ivers R, Cumming R, Mitchell P, Peduto A . Diabetes and risk of fracture: The Blue Mountains Eye Study. Diabetes Care. 2001; 24(7):1198-203. DOI: 10.2337/diacare.24.7.1198. View

Bolli G, Di Marchi R, Park G, Pramming S, Koivisto V . Insulin analogues and their potential in the management of diabetes mellitus. Diabetologia. 1999; 42(10):1151-67. DOI: 10.1007/s001250051286. View

Gunczler P, Lanes R, Paoli M, Martinis R, Villaroel O, Weisinger J . Decreased bone mineral density and bone formation markers shortly after diagnosis of clinical type 1 diabetes mellitus. J Pediatr Endocrinol Metab. 2001; 14(5):525-8. DOI: 10.1515/jpem.2001.14.5.525. View

Rithirangsriroj K, Panyakhamlerd K, Chaikittisilpa S, Chaiwatanarat T, Taechakraichana N . Osteoporosis in different age-groups and various body mass index (BMI) ranges in women undergoing bone mass measurement at King Chulalongkorn Memorial Hospital. J Med Assoc Thai. 2012; 95(5):644-9. View

Olmos J, Perez-Castrillon J, Garcia M, Garrido J, Amado J, Gonzalez-Macias J . Bone densitometry and biochemical bone remodeling markers in type 1 diabetes mellitus. Bone Miner. 1994; 26(1):1-8. DOI: 10.1016/s0169-6009(08)80157-2. View

Jara A, Bover J, Felsenfeld A . Development of secondary hyperparathyroidism and bone disease in diabetic rats with renal failure. Kidney Int. 1995; 47(6):1746-51. DOI: 10.1038/ki.1995.241. View

Lecka-Czernik B . Bone loss in diabetes: use of antidiabetic thiazolidinediones and secondary osteoporosis. Curr Osteoporos Rep. 2010; 8(4):178-84. PMC: 2947013. DOI: 10.1007/s11914-010-0027-y. View

Pastor M, Escobar-Jimenez F, Pardo M, Gonzalez A, Luna J, Requena M . Bone mineral density at time of clinical diagnosis of adult-onset type 1 diabetes mellitus. Endocr Pract. 2001; 7(5):346-51. DOI: 10.4158/EP.7.5.346. View

10.

Diamant M, Heine R . Thiazolidinediones in type 2 diabetes mellitus: current clinical evidence. Drugs. 2003; 63(13):1373-405. DOI: 10.2165/00003495-200363130-00004. View

11.

Leidig-Bruckner G, Grobholz S, Bruckner T, Scheidt-Nave C, Nawroth P, Schneider J . Prevalence and determinants of osteoporosis in patients with type 1 and type 2 diabetes mellitus. BMC Endocr Disord. 2014; 14:33. PMC: 4021186. DOI: 10.1186/1472-6823-14-33. View

12.

Thrailkill K, Lumpkin Jr C, Bunn R, Kemp S, Fowlkes J . Is insulin an anabolic agent in bone? Dissecting the diabetic bone for clues. Am J Physiol Endocrinol Metab. 2005; 289(5):E735-45. PMC: 2387001. DOI: 10.1152/ajpendo.00159.2005. View

13.

Kodama K, Tojjar D, Yamada S, Toda K, Patel C, Butte A . Ethnic differences in the relationship between insulin sensitivity and insulin response: a systematic review and meta-analysis. Diabetes Care. 2013; 36(6):1789-96. PMC: 3661854. DOI: 10.2337/dc12-1235. View

14.

Kemink S, Hermus A, Swinkels L, Lutterman J, Smals A . Osteopenia in insulin-dependent diabetes mellitus; prevalence and aspects of pathophysiology. J Endocrinol Invest. 2000; 23(5):295-303. DOI: 10.1007/BF03343726. View

15.

Jiang Y, Zhang Y, Jin M, Gu Z, Pei Y, Meng P . Aged-Related Changes in Body Composition and Association between Body Composition with Bone Mass Density by Body Mass Index in Chinese Han Men over 50-year-old. PLoS One. 2015; 10(6):e0130400. PMC: 4475062. DOI: 10.1371/journal.pone.0130400. View

16.

de Liefde I, van der Klift M, de Laet C, van Daele P, Hofman A, Pols H . Bone mineral density and fracture risk in type-2 diabetes mellitus: the Rotterdam Study. Osteoporos Int. 2005; 16(12):1713-20. DOI: 10.1007/s00198-005-1909-1. View

17.

Barrett-Connor E, Holbrook T . Sex differences in osteoporosis in older adults with non-insulin-dependent diabetes mellitus. JAMA. 1992; 268(23):3333-7. View

18.

Catalano A, Morabito N, Di Vieste G, Pintaudi B, Cucinotta D, Lasco A . Phalangeal quantitative ultrasound and metabolic control in pre-menopausal women with type 1 diabetes mellitus. J Endocrinol Invest. 2012; 36(5):347-251. DOI: 10.3275/8646. View

19.

Russo G, Giandalia A, Romeo E, Nunziata M, Muscianisi M, Ruffo M . Fracture Risk in Type 2 Diabetes: Current Perspectives and Gender Differences. Int J Endocrinol. 2017; 2016:1615735. PMC: 5164892. DOI: 10.1155/2016/1615735. View

20.

Dennison E, Syddall H, Aihie Sayer A, Craighead S, Phillips D, Cooper C . Type 2 diabetes mellitus is associated with increased axial bone density in men and women from the Hertfordshire Cohort Study: evidence for an indirect effect of insulin resistance?. Diabetologia. 2004; 47(11):1963-8. DOI: 10.1007/s00125-004-1560-y. View